SK3 Group Announces First Sales of Industry Leading Medical Cannabis Product T-Hydrocan(TM) RMC 40
April 22 2014 - 9:30AM
Marketwired
SK3 Group Announces First Sales of Industry Leading Medical
Cannabis Product T-Hydrocan(TM) RMC 40
LOS ANGELES, CA--(Marketwired - Apr 22, 2014) - SK3 Group,
Inc. (OTC Pink: SKTO) (PINKSHEETS: SKTO) is pleased to announce
that the first bottles of its new medicinal cannabis product,
T-Hydrocan™ RMC 40, will be available this Wednesday, April
23, 2014, from Pharmajanes.com, and soon thereafter from
collectives which carry the YAK Edibles line of medical marijuana
products. The "RMC" designation indicates "refined mixed
cannabinoids."
T-Hydrocan™ RMC 40 tablets contain 40 mg. of fully activated
(decarboxylated) THC, along with the attendant cannabinoids that
are found in the cannabis/hemp source material. The cannabis oils
have been thoroughly refined utilizing organic processing materials
which have been approved for contact with food, yielding a
translucent red or gold colored essential oil containing highly
concentrated cannabinoids, terpenes, terpenoids, amino acids, and
other refined elements of the essential oil of cannabis.
T-Hydrocan™ RMC 40 is packaged 8 tablets per bottle. The
suggested retail price is $35.00 per bottle.
T-Hydrocan™ RMC 40 was developed by Berkeley Bio-Organic
Research Laboratories, Inc. and is available through
Pharmajanes.com and select dispensaries throughout California. The
next product in the T-Hydrocan™ product line will be T-Hydrocan™
Whole Plant 25 tablets and capsules.
"We are pleased to get this product to market so quickly," said
Artemus Mayor, President of SK3 Group. "Licensing fees from
this product will go straight to the company's bottom line and will
give patients a high dosage capsule at an affordable price."
FDA Disclaimer These statements have not been evaluated by the
Food and Drug Administration. This product is not intended to
diagnose, treat, cure, or prevent disease. Use only as
directed.
About SK3 SK3 is a healthcare logistics and fulfillment
consultancy focused on the delivery of alternative care and
medicine. With seasoned management, breakthrough technology and
best practices, SK3 brings standardization and transparency to this
rapidly growing segment of the alternative care field.
Safe Harbor Statement This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based on the
current plans and expectations of management and are subject to a
number of uncertainties and risks that could significantly affect
the company's current plans and expectations, as well as future
results of operations and financial condition. A more extensive
listing of risks and factors that may affect the company's business
prospects and cause actual results to differ materially from those
described in the forward-looking statements can be found in the
reports and other documents filed by the company with the
Securities and Exchange Commission. The company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Relations SK3 investors@medicalgreens.com
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Mar 2024 to Apr 2024
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Apr 2023 to Apr 2024